# Dynavax Technologies Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dynavax-technologies

- Industry: Biotechnology
- Headquarters: Emeryville, US
- Website: www.dynavax.com
- Total disclosed funding: $35M
- Latest round: Series D (Apr 25, 2002)
- Investors on record: 13

## About

Dynavax Technologies Corporation is a biopharmaceutical entity specializing in the development and commercialization of innovative vaccines utilizing advanced adjuvant technology to enhance immune responses against infectious diseases.Founded in 1996 in Berkeley, US, Dynavax Technologies Corporation is focused on biopharmaceutical advancements, specifically vaccines. The company is currently headquartered in Emeryville, US. In December 2025, Sanofi S.A. agreed to fully acquire Dynavax Technologies Corporation from Care Capital, BioVeda Capital, Lotus Biosciences Ventures, Forward Ventures, Sanderling Ventures, Scale Venture Partners, Création Capital, Icon Ventures, Alta Partners, InterWest Partners, Axiom Venture Partners, HealthCap, SightLine Partners, Symphony Capital Partners Asia, Azimuth Opportunity Ltd., Deerfield Capital Management, Aspire Capital and Hercules Capital for approximately USD 2.2 billion, or USD 15.50 apiece, in an all cash public-to-private transaction. The deal was completed in February 2026, and the company was delisted from Nasdaq Global Select Market. Dynavax Technologies is a commercial-stage biopharmaceutical company concentrating on innovative vaccines that leverage established adjuvant technology. Its flagship product, HEPLISAV-B®, is a novel hepatitis B vaccine designed for enhanced protection and administered in a two-dose regimen. Additionally, CpG 1018®, an adjuvant integral to vaccine development, further emphasizes its commitment to addressing public health needs through improved vaccination solutions. The company serves healthcare providers, government health agencies, and global pharmaceutical partners, primarily in the United States, Europe, and select international markets. The company's revenue is primarily derived from the sales of HEPLISAV-B® and CpG 1018®, through B2B relationships with healthcare providers and pharmaceutical distributors, ensuring widespread distribution of its vaccine solutions.Dynavax Technologies Corporation aims to expand its product offerings and market reach. Plans include the ongoing development of additional vaccine candidates, with specific timelines and product details to be determined. New markets will be targeted for expansion, particularly in regions where access to improved immunization solutions is critical.

## Funding rounds

- Series D, Apr 25, 2002, $35M — Alta Partners, Care Capital, Forward Ventures, InterWest Partners, Sanderling Ventures, HealthCap, BioVeda Capital, SightLine Partners, Scale Venture Partners, Axiom Venture Partners, Création Capital, Icon Ventures, Lotus Biosciences Ventures

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series D
- Care Capital (https://capitalatlas.ai/funds/care-capital) — Series D
- Forward Ventures (https://capitalatlas.ai/funds/forward-ventures) — Series D
- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series D
- Sanderling Ventures (https://capitalatlas.ai/funds/sanderling-ventures) — Series D
- HealthCap — Series D
- BioVeda Capital (https://capitalatlas.ai/funds/bioveda-capital) — Series D
- SightLine Partners — Series D
- Scale Venture Partners (https://capitalatlas.ai/funds/scale-venture-partners) — Series D
- Axiom Venture Partners (https://capitalatlas.ai/funds/axiom-venture-partners) — Series D
- Création Capital — Series D
- Icon Ventures (https://capitalatlas.ai/funds/icon-ventures) — Series D
- Lotus Biosciences Ventures (https://capitalatlas.ai/funds/lotus-biosciences-ventures) — Series D